Assuming
1. Phase 3 success in PMS, Pitt Hopkins, and Anglemans Syndrome
2. USD $466k per patient per year
3. Penetration of 50% of the low end estimated patient population in the US (17k, 6k and 12k respectively)
that puts annual sales at USD $8,155,000,000
which at 20% royalties puts annual revenue at USD $1,631,000,000
which at todays exchange rate is AUD $2,609,600,000
which is over AUD $20 per share annual revenue.
For what it's worth...
Assuming1. Phase 3 success in PMS, Pitt Hopkins, and Anglemans...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.26 |
Change
-0.280(2.23%) |
Mkt cap ! $1.525B | |||
| Open | High | Low | Value | Volume |
| $12.45 | $12.45 | $11.88 | $6.952M | 570.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 231 | $12.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.32 | 1979 | 2 |
View Market Depth
| Last trade - 16.13pm 23/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |